Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

TL;DR: The preliminary findings suggest that negative D-dimer may identify patients with history of previous VTE at low risk of recurrences, but this approach should be tested in larger trials in highly selected patients.

TL;DR: The presenting symptoms can be subtle, and therefore objective testing is necessary for diagnosis, and more than one test may be required to exclude the diagnosis.

TL;DR: When IC-DVT is not ruled out in the ED, the suggested algorithm, although not prospectively validated by a controlled study, offers an approach to diagnosis that is consistent with current data and recommendations.

TL;DR: In patients with a first unprovoked pulmonary embolism, the HERDOO2 score is able to identify patients withA low recurrence risk after treatment discontinuation and addition of PVOI improves accuracy of all scores.

TL;DR: In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding.

TL;DR: Guyatt et al. as mentioned in this paper presented the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) and provided specific management recommendations for the first 1 or 2 days for most individuals.

TL;DR: The clinical course of a first episode of symptomatic deep venous thrombosis in a large consecutive series of patients who had long-term follow-up was assessed and the potential risk factors for these three outcomes were evaluated.

TL;DR: It is shown that patients with symptomatic proximal DVT may benefit from fitted compression stockings for at least 3 months to reduce the incidence of the postthrombotic syndrome, and patients with VTE who receive adequate anticoagulation generally do not die of recurrent disease.